

PROSPECTION

Prospection submission

REVIEW OF AUTHORITY REQUIRED PBS LISTINGS

DR PETER CRONIN



Review of Authority Required PBS Listings

Prospection is a health analytics company. We have considerable experience working with the PBS 10% sample with industry and have a purpose built platform PharmDash for this purpose.

A common issue that we are faced with is trying to understand the use of a particular medication for a particular indication. In this respect the current structuring of the PBS has some limitations. For example, biologics such as adalimumab have multiple indications; rheumatoid arthritis, psoriatic arthritis etc. Each indication has a separate item code in this case which greatly enhances the ability to provide useful and meaningful information to support quality use of medicines research and PBAC submissions etc.

There are other cases where a drug may have multiple indications where it is more difficult to determine the indication the drug was prescribed for. This could occur where there are multiple indications per item e.g. docetaxal (item 5585Y) is Authority required (streamlined) but has multiple indications within the item for ovarian cancer, prostate cancer etc. Whilst these all have four digit codes we have experienced an apparent issue with the quality of the data capture that means it is difficult to separate by indication.

We support efficiencies in the authority scripts processes in general. If changes to listings are to occur, we believe that consideration should be given to the processes and item code / authority code structures. Any changes should enhance the medication data capture for important research purposes. These research activities support the goal of improving Australia's health which could be improved with better data on medication use by indication.

Dr Peter Cronin

Managing Director

Prospection

Ph: +61 2 9209 4035

peter.cronin@prospection.com.au